findmyKOL

Robert Tamayev, MD-PHD

Basic profile

Allergy & Immunology

ORCIDNone on fileNPI↗
✓ Full record
RegionRego Park, NY · NortheastSpecialtyAllergy & ImmunologyFocusRheumatology/Immunology
Active KOLfindmyKOL type: NationalLatest publication2021Online presenceNot yet checkedPayments2021 onwardNIH funding2011–2011Why? →

Robert Tamayev is a Rheumatology/Immunology physician. OpenAlex indexes 25 publications with 756 citations (h-index 13).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
25publications

Distinct works indexed by OpenAlex.

756citations

Total citations across indexed works.

13h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
36companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2011–2011

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

9876 Queens Blvd # 1jk
Rego Park, NY 113744398

Telephone

347-336-5972

Provider last certified this registry record 7 Jun 2022.

View the NPPES registry record

Industry payments

36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    60%
    Corticosteroid21.1%
    Fluticasone Propionate61%Trelegy Ellipta19%Mometasone Furoate13%Xhance7%
    Part D<11 patients
    Histamine-1 Receptor Antagonist19.1%
    Azelastine Hcl100%
    Part D≥69 patients

    + 5 more classes in this area

  • Dermatology

    24.6%
    Corticosteroid14.6%
    Triamcinolone Acetonide68%Halobetasol Propionate32%
    Part D≥48 patients
    Interleukin-4 Receptor alpha Antagonist7.6%
    Dupixent Syringe100%
    Part D≥13 patients

    + 2 more classes in this area

  • Nervous system

    5.6%
    Antihistamine3.1%
    Hydroxyzine Hcl100%
    Part D<11 patients
    Gabapentinoids2.5%
    Gabapentin100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2011–2011 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”